Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-3: brigimadlin + ezabenlimab vs gemcitabine + docetaxel in advanced TP53 wild-type soft tissue sarcoma
jRCT2031240013Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of brigimadlin and ezabenlimab in soft tissue sarcoma (STS) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Progression-free survival and Overall survival. Started Jun 2024; status: completed.
02
Drugs
brigimadlinezabenlimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2031240013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240013.